Recently Featured

FDA Issues Temporary Guidance on Compounding Starter Parenteral Nutrition for Neonates

September 24, 2026
The FDA has released new guidance outlining its regulatory and enforcement priorities concerning the compounding of specific starter parenteral nutrition drug products for neonates. This guidance specifically targets outsourcing facilities, State-licensed pharmacies, and Federal facilities that are not registered with the FDA, indicating a focused effort to ensure the safety and efficacy of these critical…

Medicines Discovery Catapult Invests £1 Million in U.K. Biotechs Addressing Chronic Diseases

September 24, 2026
Medicines Discovery Catapult (MDC) has announced a £1 million investment in two U.K. biotech companies, Flip Therapeutics and Nascent Therapeutics, both focused on innovative treatments for chronic diseases such as psoriasis and neurodegenerative disorders. This funding, sourced from Innovate UK, aims to propel the development of high-potential therapies that address significant unmet medical needs. Alongside…

Micro-Bladder Model Reveals Phage Therapy’s Potential in Combatting Recurrent UTIs

September 24, 2026
Researchers at the Centre for Kidney and Bladder Health, University College London, have developed a novel human 3D micro-bladder model that demonstrates the efficacy of phage therapy in addressing recurrent urinary tract infections (UTIs). This innovative model allows for the simulation of real urinary tract conditions, highlighting the limitations of traditional antibiotics against bacteria that…

C. difficile Colonization in Infants May Have Long-Term Health Implications

September 24, 2026
Recent research from the Children’s Hospital of Philadelphia (CHOP) has upended long-standing beliefs regarding the bacterium Clostridioides difficile (C. diff) and its effects on infants. Traditionally viewed as harmless due to the absence of symptoms in this population, new findings indicate that early-life colonization may significantly alter gut development and immune responses, potentially leading to…

Ongoing Cases